Saluda Medical Announces First U.S. Surgical Cases Using Newly Approved CAP24™ Paddle Lead

Thu, 16 Jul 2026 09:40:00 -0400

BLOOMINGTON, Minn., July 16, 2026 /PRNewswire/ -- Saluda Medical, Inc. (ASX: SLD, "Saluda" or the "Company"), a commercial‑stage medical device company advancing closed‑loop neuromodulation for chronic neurological conditions, today announced the first U.S. surgical cases using the newly FDA‑approved Evoke® CAP24™ paddle lead.

Saluda Medical Announces First U.S. Surgical Cases Using Newly Approved CAP24™ Paddle Lead

Thu, 16 Jul 2026 09:40:00 -0400

FDA clears Saluda Medical's CAP24 paddle lead for spinal cord stimulation

Tue, 30 Jun 2026 09:15:17 -0400

Saluda Medical (ASX: SLD) announced that the U.S. Food and Drug Administration has approved its CAP24 surgical paddle lead, allowing the device to be marketed and sold in the United States.

The CAP24 is a paddle lead designed for use with Saluda's Evoke System and EVA Sensing Technology in spinal cord stimulation (SCS) procedures. Paddle leads are an alternative to percutaneous leads and are generally preferred by neurosurgeons and orthopedic surgeons, who account for approximately 30% of all SCS implants in the U.S., according to the company.

The device features a 24-electrode, three-column configuration and is designed to sense and measure evoked

FDA clears Saluda Medical's CAP24 paddle lead for spinal cord stimulation

Tue, 30 Jun 2026 09:15:17 -0400

Saluda Medical (ASX: SLD) announced that the U.S. Food and Drug Administration has approved its CAP24 surgical paddle lead, allowing the device to be marketed and sold in the United States.

The device features a 24-electrode, three-column configuration and is designed to sense and measure evoked

FDA clears Saluda Medical's CAP24 paddle lead for spinal cord stimulation

Tue, 30 Jun 2026 09:15:17 -0400

Saluda Medical (ASX: SLD) announced that the U.S. Food and Drug Administration has approved its CAP24 surgical paddle lead, allowing the device to be marketed and sold in the United States.

The device features a 24-electrode, three-column configuration and is designed to sense and measure evoked

Saluda Medical Receives U.S. FDA Approval for New CAP24™ Surgical Paddle Lead

Tue, 30 Jun 2026 09:15:00 -0400

BLOOMINGTON, Minn., June 30, 2026 /PRNewswire/ -- Saluda Medical, Inc. (ASX: SLD, "Saluda" or the "Company"), a commercial-stage medical device company focused on developing treatments for chronic neurological conditions using its novel closed-loop neuromodulation platform, today announced that the U.S. Food and Drug Administration ("FDA") has approved Saluda's CAP24 paddle lead, allowing it to be marketed and sold in the U.S. Paddle leads are an alternative to percutaneous leads and this approval enables the Company to target neurosurgeons and orthopedic surgeons, who generally prefer the surgical

Saluda Medical Receives U.S. FDA Approval for New CAP24™ Surgical Paddle Lead

Tue, 30 Jun 2026 09:15:00 -0400

Saluda Medical Receives U.S. FDA Approval for New CAP24™ Surgical Paddle Lead

Tue, 30 Jun 2026 09:15:00 -0400

Saluda Medical Receives U.S. FDA Approval for New CAP24™ Surgical Paddle Lead

Tue, 30 Jun 2026 09:15:00 -0400

Saluda Medical Receives U.S. FDA Approval for New CAP24™ Surgical Paddle Lead

Tue, 30 Jun 2026 09:15:00 -0400

Saluda Medical Receives U.S. FDA Approval for New CAP24™ Surgical Paddle Lead

Tue, 30 Jun 2026 09:15:00 -0400

Saluda Medical Receives Regulatory Approval for EVA™ Sensing Technology in Europe with recognition in Australia

Thu, 08 Jan 2026 05:00:00 -0400

MINNEAPOLIS, Jan. 8, 2026 /PRNewswire/ -- Saluda Medical, Inc. (ASX:SLD, "Saluda" or the "Company"), a commercial-stage medical device company focused on developing treatments for chronic neurological conditions using its novel closed-loop neuromodulation platform, announced that, as expected, its next-generation EVA™ Sensing Technology has now received CE certification for commercialization in Europe with recognition of this approval in Australia. This follows FDA approval of EVA in December 2024.

Saluda Medical Receives Regulatory Approval for EVA™ Sensing Technology in Europe with recognition in Australia

Thu, 08 Jan 2026 05:00:00 -0400

Saluda Medical Raises $150M USD to Fuel Growth Following ASX IPO